TRIALS WILL SHOW VALUE OF MEDICAL MARIJUANA

I write in response to Rich Figel's story on overhauling drug policy
("Addicted to Life," Star-Bulletin, Aug. 5). To tackle this problem
head-on, we need to start at the top. I work for MAPS (the
Multidisciplinary Association for Psychedelic Studies), an
organization that recently won a landmark lawsuit against the Drug
Enforcement Agency that seeks a license to grow marijuana for Food
and Drug Administration IND (Investigational New Drug) trials to
determine medical value.

There's one more step in the approval process. Reps. John Olver
(D-Mass.) and Dana Rohrabacher (R-Calif.) are co-sponsoring a
congressional sign-on letter urging the DEA to accept the recommended
ruling. We urge your readers to visit www.maps.org to find out how
they can help.

Terri Thatcher

Multidisciplinary Association for Psychedelic Studies Ben Lomond, Calif.